Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.44 |
| ▸ | BCHE | P06276 | 4/20 | 0.43 |
| ▸ | ACHE | P22303 | 4/20 | 0.43 |
| ▸ | BACE1 | P56817 | 4/20 | 0.43 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4485008 | 0.88 | P2RX7 (0.45) | SIGMAR1BCHEACHEBACE1TEAD1 | |
| SCHEMBL4485246 | 0.86 | BCHE (0.43) | SIGMAR1BCHEACHEBACE1TEAD1 | |
| SCHEMBL4483441 | 0.83 | ALDH1A1 (0.52) | SIGMAR1TMEM97ALDH1A1NPC1 | |
| SCHEMBL28812079 | 0.79 | SIGMAR1 (0.48) | SIGMAR1BCHEACHEBACE1TEAD1 | |
| SCHEMBL4482088 | 0.79 | OPRL1 (0.53) | BCHEACHEBACE1ALDH1A1L3MBTL1 | |
| SCHEMBL18919693 | 0.78 | BCHE (0.46) | BCHEACHEBACE1TEAD1ALDH1A1 | |
| SCHEMBL18919696 | 0.78 | BCHE (0.46) | BCHEACHEBACE1TEAD1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28812632 | 0.78 | SIGMAR1 (0.47) | SIGMAR1BCHEACHEBACE1TEAD1 | |
| SCHEMBL736320 | 0.77 | OPRL1 (0.47) | BCHEACHEBACE1 | |
| SCHEMBL4476067 | 0.77 | SIGMAR1 (0.53) | SIGMAR1BCHEACHEBACE1TEAD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | ELI LILY AND COMPANY (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | SLC6A2, SLC6A4, HTR5A | SIGMAR1 539/4885BCHE 2544/4885ACHE 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.